Shilpa Medicare Limited (530549) Earnings Call Transcripts

Shilpa Medicare Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Shilpa Medicare Limited reported record quarterly revenues of INR 439 crores, reflecting a robust 30% year-on-year growth. For the full fiscal year, revenues reached INR 1,549 crores, up 18% from the previous year. The company achieved an adjusted PAT of INR 87 crores for the quarter and INR 232 crores for the year, marking a significant 135% increase. Management highlighted strong growth across key segments, particularly in formulations and biologics, and signaled a positive outlook for FY '27, emphasizing ongoing product launches and pipeline advancements.

Reported metrics

Guidance from management

Management expects continued growth in FY '27 driven by new product launches and an expanding pipeline, although they did not provide specific revenue or earnings guidance.

What management said

Yes. Thank you, Kiran. So I think on the U.S. revenue front, as you rightly mentioned, right, we have seen an increase in revenue, and that will most likely continue in the FY '27 also. Only against last year, this year, you will see we have stopped selling our generic product, which was azacitidine in U.S. So that supplies to U.S., we don't want to do it because the margin is no longer sustainable for us. So now we ...

No, Kiran, I think one thing I can tell you, if you see NorUDCA, we have launched the product in Q3, right, sometime in November, December. And if you see from there today, we are in Q1. So we have seen -- just on quarter-on-quarter basis itself, we have seen a steep growth. So we have to see how the trajectory will be for the upcoming quarters because the total disease, the curability duration is 6 months. So once t...

What analysts pressed on

Analysts expressed concerns about the slower growth in U.S. formulation revenues despite market share gains by partners. They questioned the sustainability of revenue from certain generic products and sought clarity on future growth drivers.

Main topics on the call

• Record Revenue Growth — Shilpa Medicare achieved its highest ever quarterly revenue of INR 439 crores, up 30% YoY, and full-year revenue of INR 1,549 crores, growing 18%. Management stated, "We have delivered our highest ever quarterly revenues...
• Strong EBITDA Performance — The company reported an EBITDA of INR 121 crores for Q4 FY '26, a 40% increase YoY, with an EBITDA margin of 28%. For the full year, EBITDA was INR 445 crores, reflecting a 30% growth. Management noted, "We continue to r...
• Biologics Segment Growth — The biologics segment saw revenue growth of approximately 100% YoY, driven by strong deal momentum in the CDMO business. Management indicated, "The strong growth was driven by continued deal momentum that we are witnessi...
• Formulations Pipeline Expansion — Formulations revenue grew 54% YoY in Q4 FY '26, with significant contributions from new product launches. Management mentioned, "We continue advancing a pipeline of complex products and our strategy of developing and lau...

Read the full Shilpa Medicare Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 13 Shilpa Medicare Limited earnings call transcripts on record, spanning August 11, 2023 to August 5, 2026. Based on this history, Shilpa Medicare Limited reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

530549

Exchange

BSE

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

13

First call

August 11, 2023

Most recent

August 5, 2026

Reporting cadence

quarterly